Neptune Medical Completes $97 Million Series D

<p><strong>BURLINGAME<&sol;strong> &&num;8212&semi; Neptune Medical&comma; a developer of advanced medical devices with a primary focus on gastrointestinal robotics&comma; has announced the successful spinout of its subsidiary&comma; Jupiter Endovascular&comma; following the completion of a &dollar;97 million Series D financing&period; Sonder Capital and Olympus Corporation of the Americas were significant participants in this round&comma; along with investments from other existing and new investors&period;<&sol;p>&NewLine;<p>This financing will strengthen Neptune Medical as a gastrointestinal-focused company expanding into robotics for GI disease&comma; as evidenced by the recent appointment of medical robotics pioneer Dr&period; Fred Moll as Chairman of the Board&period; It will also enable Jupiter Endovascular to focus on its novel endovascular technology platform&period;<&sol;p>&NewLine;<p>&&num;8220&semi;Neptune Medical is thrilled to announce the successful closure of our Series D financing and the spinout of Jupiter Endovascular&period; These significant milestones allow us to sharpen our focus on GI robotics while empowering Jupiter to drive innovation in endovascular treatments&comma;&&num;8221&semi; said Alex Tilson&comma; Founder and CEO of Neptune Medical&period; &&num;8220&semi;We are grateful to our investors for their unwavering support and confidence in our vision&period;&&num;8221&semi;<&sol;p>&NewLine;<p>Dr&period; Moll commented&comma; &&num;8220&semi;The spinout of Jupiter Endovascular is a strategic move that aligns with our long-term goals&period; With dedicated resources and leadership&comma; Jupiter is well-positioned to revolutionize endovascular therapies&period; Meanwhile&comma; Neptune will continue to push the boundaries in GI robotics&comma; delivering transformative solutions to patients and healthcare providers&period; We intend for both companies to lead the way in innovating within their respective specialties&period;&&num;8221&semi;<&sol;p>&NewLine;<p>Chief Strategy Officer for Olympus&comma; Gabriela Kaynor&comma; added&comma; &&num;8220&semi;We are excited to participate in this financing round for Neptune Medical&period; We believe Neptune&&num;8217&semi;s innovative approach to endoscopy has the potential to elevate the standard of care by improving patient outcomes&period;&&num;8221&semi;<b><&sol;b><&sol;p>&NewLine;